HeartSciences Showcases MyoVista® Wavelet ECG at 2018 China International Medicinal Equipment Fair (CMEF)
Hall 5.1 USA-CEO Center (S26-32/R19-25-5)
About HeartSciences
HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista wavECG is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences’ mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to proprietary informatics, the MyoVista wavECG device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG device is not currently FDA approved for commercial sale or distribution in the United States.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180409005020/en/
Website: http://www.heartsciences.com
Contact
HeartSciences
Gene Gephart
+1-737-346-1089
gene.gephart@heartsciences.com
Investor Contact
Zimmons International Communications
Jennifer K. Zimmons
+1-917-214-3514
jzimmons@zimmonsic.com
This news is a press release provided by HeartSciences.
-
2018년 4월 11일 18:10
